-by Susie Bragg, RN BSN (Nurse Educator)
If you haven’t heard of “Sema” yet, you certainly will as this relatively new weight loss miracle transforms appetite suppression in an entirely different way. In fact, Svelte Medical Director, Richard Bragg, MD has lost close to 70 pounds on the weekly injection since August of 2022. To make a long story short, “Sema” is the generic form of Wegovy, a GLP-1 type diabetic drug manufactured by pharma giant Novo Nordisk that was approved for weight loss by the FDA in 2021.
All drugs have pharmaceutical trade names and generic names. The generic for Wegovy and it’s close cousin Ozempic, another Novo Nordisk marketed diabetic titrated injectable, is Semaglutide. Due to manufacturing problems at Novo in late 2021, the FDA issued authorization for 503 A & B compounding pharmacies across the US to compound Semaglutide in an attempt to meet the roaring demand for the GLP-1 treatment.
Studies of the drug have demonstrated it’s remarkable ability to suppress appetite leading to overall health and well being for the patient. Visceral fat loss, decreased blood pressure, stable insulin and sugar levels are all outcomes from the treatment which is exactly what endocrinologists and internal medicine physicians want. The appetite for Semaglutide in the US grows daily as Americans notice friends and families on the treatment are slimming down dramatically.
“Svelte Sema“ is a new program offered at all Svelte clinics since September of 2022 & the response has been overwhelming. The big advantage? People can access the treatment without the “diabetic” diagnosis and lose that weight they are tired of lugging around. Trade name GLP-1 drugs like Wegovy and Ozempic are very expensive ($900- $1200 for a one month pen) and the starter vial of generic Semaglutide is only $395 for a 6 week injection series thus making the weight loss phenom treatment affordable.
How long the emergency compounding order from the FDA will last is anybody’s guess however Novo Nordisk is promising to meet the market demand now and pressuring the US to cease and desist with the compounding of Semaglutide immediately. When this happens, Svelte Medical is committed to providing alternative GLP-1 injection therapy to it’s clients and will pivot to alternative therapies. Until the pharmacies are restricted from compounding Semaglutide, Svelte will continue to offer the therapy.
If YOU are the least bit interested in seeing what Semaglutide can do for your waistline, we recommend making an appointment as soon as possible since we have no idea when the compounders will be ordered to cease and desist. We hope we have time because at Svelte, we are completely thrilled with the results our clients are experiencing!
Side effects include nausea, cramping, constipation, gas, diarrhea & loss of appetite. The drug is titrated to acclimate the client’s body to the treatment with minimal side effects. At Svelte, your first “starter” vial of Semaglutide is a very low dose and 90% of our clients report minimal side effects on the first vial at the lowest dose. The second vial is stronger and this is where we see significant weight loss. The treatment schedule can be seen here:
To schedule an appointment or find out more, call us at (407)804-5200